Progress in targeted inhibition of aerobic glycolysis combined with immunotherapy for renal cell carcinoma.
- Author:
Kun ZHANG
1
,
2
;
Mengyao RU
1
,
2
;
Jiayuan WANG
1
,
2
;
Jumei ZHAO
3
;
Lan SHEN
4
Author Information
1. Medical school of Yan'an University, Yan'an 716000
2. State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Basic Medicine Science Academy, Air Force Medical University, Xi'an 710032, China.
3. Medical school of Yan'an University, Yan'an 716000. *Corresponding authors, E-mail: jmz2003.stu@163.com.
4. State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Basic Medicine Science Academy, Air Force Medical University, Xi'an 710032, China. *Corresponding authors, E-mail: lanshen@fmmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Renal Cell/therapy*;
Immunotherapy;
Glycolysis;
Metabolic Reprogramming;
Kidney Neoplasms/therapy*;
Tumor Microenvironment
- From:
Chinese Journal of Cellular and Molecular Immunology
2024;40(1):74-79
- CountryChina
- Language:Chinese
-
Abstract:
Tumor aerobic glycolysis is one of the main features of tumor metabolic reprogramming. This abnormal glycolytic metabolism provides bioenergy and biomaterials for tumor growth and proliferation. It is worth noting that aerobic glycolysis will not only provide biological materials and energy for tumor cells, but also help tumor cells to escape immune surveillance through regulation of immune microenvironment, thereby resisting tumor immunotherapy and promoting tumor progression. Based on the pathogenesis of renal cell carcinoma, this paper describes the characteristics of aerobic glycolysis, the effect of glycolytic metabolism on the immune microenvironment of renal cell carcinoma, the effect of glycolysis inhibitors on the immune microenvironment of renal cell carcinoma, and the prospect of glycolysis inhibitors combined with immune checkpoint inhibitors in the treatment of renal cell carcinoma.
